In addition, urinary CCL14 can further be used to discriminate eligibility thresholds to predictively enrich the target population in clinical trials that aim to evaluate therapeutic strategies in patients at high risk for experiencing persistent severe AKI and its sequelae [14]. This evidence concerns the gene CCL14 and acute kidney injury.